Global Leading Market Research Publisher QYResearch announces the release of its latest report “Coal Tar Topical OTC – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Coal Tar Topical OTC market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Coal Tar Topical OTC was estimated to be worth US320millionin2025andisprojectedtoreachUS320millionin2025andisprojectedtoreachUS 450 million by 2032, growing at a CAGR of 5.0% from 2026 to 2032.
For dermatologists, primary care physicians, and patients with chronic plaque psoriasis and seborrheic dermatitis, the core therapeutic challenge is precise: managing hyperproliferation (reduced epidermal turnover time from 28 days to 3-5 days in psoriatic plaques), scaling (parakeratosis, stratum corneum thickening), and inflammation using over-the-counter (OTC) formulations (shampoos, creams, ointments, foams, solutions, gels) that provide keratolytic (desquamation, soften and remove scales), antiproliferative (reduced DNA synthesis, mitotic activity, epidermal hyperplasia), and anti-inflammatory effects, while avoiding the risks and side effects of prescription corticosteroids (skin atrophy, telangiectasia, rebound flare) and calcineurin inhibitors (burning, lymphoma risk), with a well-established safety profile for long-term maintenance (chronic use). The solution lies in coal tar topical OTC—derived from bituminous coal distillation, containing polycyclic aromatic hydrocarbons (PAHs, e.g., naphthalene, anthracene, phenanthrene, acridine, carbazole, fluorene, pyrene, benzo[a]pyrene). USP-grade coal tar concentrations: 0.5-5% for OTC (0.5-5% crude coal tar (CCT) or coal tar solution (CTS), 1-2% most common). FDA monograph for OTC psoriasis treatment (approved). Unlike prescription coal tar (higher concentration, 5-20% for inpatient goeckerman regimen, 20% for resistant plaques), OTC products balance efficacy with cosmetic acceptability (odor, staining). As patients seek steroid-sparing, non-prescription, long-term management solutions (psoriasis is incurable, chronic relapsing), the OTC coal tar market grows.
Coal Tar Topical OTC is an over-the-counter (OTC) product used to treat psoriasis and seborrhea dermatitis. Coal tar topical is available under the following different brand names: Fototar, Medotar, Oxipor VHC, Polytar Soap, Psorent, Psoriasin, and Taraphilic.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5984771/coal-tar-topical-otc
1. Industry Segmentation by Strength and Indication
The Coal Tar Topical OTC market is segmented as below by Type (Coal Tar Content):
- 0-5% – 52% market share (2025). Most common OTC (0.5%, 1%, 2%, 3%, 5%). Shampoos (1-2%), creams (1-5%). Suitable for mild-moderate scalp psoriasis, body plaques, seborrheic dermatitis.
- 5-10% – 22% market share. Stronger OTC (some states prescription required, but many OTC). For thicker plaques, scalp psoriasis resistant to lower strength.
- 10-20% – 18% market share. Strongest OTC (max 20%, some states prescription). For chronic plaque psoriasis.
- 80-86% – 8% share (industrial grade, denatured. Not for topical OTC? Possibly raw material).
By Application – Psoriasis (plaque psoriasis, scalp psoriasis, guttate, inverse) leads with 64% market share. Seborrhea Dermatitis (dandruff, scalp scaling, face, ears, chest, groin) 28% share. Others (eczema, atopic dermatitis, neurodermatitis, lichen planus) 8% share.
Key Players – OTC coal tar manufacturers: Humco (US, coal tar preparations), NeoStrata (Psorent line), ICM Pharma (Singapore, Taraphilic), Prestige Consumer Healthcare Inc (Psoriasin). Spectrum Chemical (raw material, API supplier). TMT Pharmaceutical Laboratories (US), PCCA (custom compounding, PCCA). Dermawin Pharmaceuticals (US, Dermawin). Penta Manufacturing Company (raw material), TriDerma.
2. Technical Challenges: Odor, Staining, and Irritation
Cosmetic acceptability (odor, staining) — Coal tar has strong characteristic smell (phenolic, naphthalene). Faint after shampooing. Staining (clothing, bedding) — patients advised to use old clothes. Reformulations (fragrance, clear vehicle).
Skin irritation (folliculitis) — May cause dryness, burning, stinging, irritation, photosensitivity (increased UV sensitivity). Advise sun avoidance (UV lamps, sunlight), sunscreen use.
Potential carcinogenic risk (PAH) — Crude coal tar contains benzo[a]pyrene (group 1 carcinogen, IARC). Topical application (psoriasis) not proven to increase cancer risk in humans (FDA allows OTC). However long-term occupational exposure (chimney sweeps, coke oven workers (scrotal cancer)) known.
3. Policy, User Cases & Market Dynamics (Last 6 Months, 2025-2026)
- FDA OTC Monograph (M016) (2025 update) – Psoriasis: Coal Tar (0.5-5%) Category I (safe and effective). Seborrhea: Coal Tar (0.5-5%) Category I. Labeling claims (controls itching, flaking, scaling, redness).
- REACH (EC) 1907/2006 (2025) – Restriction of PAH in consumer products (≤5 ppm BaP (benzo[a]pyrene)) for rubber/plastics. Topical coal tar exempt (drug).
- China NMPA (2026) (National Medical Products Administration) – Coal tar OTC classification abroad.
User Case – Scalp Psoriasis (mild-moderate, body surface area <5%) — OTC coal tar shampoo (2%) used 2-3 times per week, leave on 5-10 minutes. Reduce scaling, itching, plaque thickness. Maintenance therapy (chronic).
User Case – Seborrheic dermatitis (dandruff) — Coal tar shampoo (1%) for mild-moderate cases (along with ketoconazole, zinc pyrithione). Antifungal + keratolytic.
4. Exclusive Observation: Coal Tar + Salicylic Acid Combination
Salicylic acid (SA) 2-3% (keratolytic, breaks down thick scale) + coal tar (2-5%) synergistic. SA penetrates plaques, coal tar acts on epidermis. Available OTC (Psoriasin, MG217, Neutrogena T/Gel).
5. Outlook & Strategic Implications (2026-2032)
Through 2032, the coal tar topical OTC market will segment: low strength (0.5-5%) for OTC (scalp psoriasis, seborrhea) — 60% value, 4-5% CAGR; medium-high strength (5-20%) for resistant plaques — 30% value, 5-6% CAGR; combination (coal tar + salicylic acid) — 10% value, 6% CAGR. Key success factors: cosmetic acceptability (reduced odor/staining), FDA monograph compliance, and packaging (pump, tube). Suppliers who fail to transition from prescription coal tar (inpatient) to OTC self-care — and who cannot address odor/staining concerns — will lose chronic psoriasis/seborrhea market share.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
